Potassium-sparing agents during diuretic therapy in hypertension.
Three pharmacological agents in use as "potassium-sparing" drugs have been tested by serial measurements of total exchangeable potassium (K(E)) during 4 to 12 weeks of oral diuretic therapy in hypertensive subjects. Triamterene seemed ineffective in the dosage used (50 mg twice daily). Spironolactone (25 mg twice daily) reduced K loss to a considerable extent, while Slow-K (32 mEq daily) completely reversed previous K(E) deficits. Plasma K levels were a poor indication of degree of K(E) restoration.
D000328:Adult; D000368:Aged; D002752:Chlorthalidone / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D011188:Potassium / Q000097:blood / Q000378:metabolism*; D011191:Potassium Deficiency / Q000517:prevention & control; D013148:Spironolactone / Q000627:therapeutic use; D014223:Triamterene / Q000627:therapeutic use
D004232:Diuretics; D013148:Spironolactone; D002752:Chlorthalidone; D011188:Potassium; D014223:Triamterene